The most relevant GLUTs in cancer include GLUT1 (SLC2A1), GLUT3 (SLC2A3) and GLUT4 (SLC2A4), which are highly expressed in breast, CRC and lung cancers, with a high affinity for glucose and commonly associated with poor prognosis and therapy resistance [32,81,82]. This evidence concerns the gene SLC2A4 and colorectal carcinoma.